Zeolitic imidazolate framework-L (ZIF-L) has great potential as a doxorubicin hydrochloride (DOX) drug carrier for oral chemotherapy applications. This medical application will greatly support the development of cancer treatment and reduce the cancer fatality rate. However, ZIF-L as a type of metal-organic framework (MOFs) faces several challenges to be implemented in biomedical applications which impact the drug loading and release mechanisms.
